$SLDB
Solid Biosciences Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021053726 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $3.537M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.143M $5.180M $5.530M
YoY Change 37.9% -25.25% 3.17%
% of Gross Profit
Research & Development $14.43M $16.05M $13.45M
YoY Change -10.12% -29.57% -37.76%
% of Gross Profit
Depreciation & Amortization $752.0K $766.0K $1.334M
YoY Change -1.83% 0.26% 102.74%
% of Gross Profit
Operating Expenses $21.57M $21.23M $18.97M
YoY Change 1.59% -28.56% -29.66%
Operating Profit -$18.03M
YoY Change
Interest Expense -$20.00K -$13.00K
YoY Change -104.93% -103.51%
% of Operating Profit
Other Income/Expense, Net $48.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Pretax Income -$17.98M -$21.25M -$18.99M
YoY Change -15.37% -27.38% -28.42%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.98M -$21.25M -$18.99M
YoY Change -15.36% -27.38% -28.42%
Net Earnings / Revenue -508.43%
Basic Earnings Per Share -$2.40
Diluted Earnings Per Share -$160.1K -$440.0K -$394.3K
COMMON SHARES
Basic Shares Outstanding 7.488M
Diluted Shares Outstanding 7.488M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $229.8M $24.80M $40.40M
YoY Change 826.45% -76.53% -40.05%
Cash & Equivalents $109.7M $24.80M $40.44M
Short-Term Investments $120.1M $0.00 $0.00
Other Short-Term Assets $8.456M $2.400M $3.100M
YoY Change 252.33% -69.23% -71.56%
Inventory
Prepaid Expenses
Receivables $594.0K
Other Receivables $0.00
Total Short-Term Assets $238.8M $27.20M $43.50M
YoY Change 777.98% -76.03% -44.46%
LONG-TERM ASSETS
Property, Plant & Equipment $6.886M $8.869M $9.582M
YoY Change -22.36% -21.99% -19.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.072M $500.0K $500.0K
YoY Change 314.4% 139.23% 139.23%
Total Long-Term Assets $10.18M $13.30M $14.50M
YoY Change -23.49% -23.71% -19.37%
TOTAL ASSETS
Total Short-Term Assets $238.8M $27.20M $43.50M
Total Long-Term Assets $10.18M $13.30M $14.50M
Total Assets $249.0M $40.50M $58.00M
YoY Change 514.78% -69.07% -39.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.148M $4.100M $2.800M
YoY Change 1.17% 27.73% -50.0%
Accrued Expenses $8.003M $8.550M $8.315M
YoY Change -6.4% -25.43% 38.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $226.0K $200.0K $200.0K
YoY Change 13.0% 0.0% 0.0%
Total Short-Term Liabilities $22.54M $14.80M $13.20M
YoY Change 52.31% -11.64% -3.45%
LONG-TERM LIABILITIES
Long-Term Debt $353.0K $600.0K $600.0K
YoY Change -41.17% -25.0% -25.0%
Other Long-Term Liabilities $2.728M $2.900M $3.500M
YoY Change -5.93% -40.82% -33.96%
Total Long-Term Liabilities $3.081M $3.500M $4.100M
YoY Change -11.97% -38.6% -32.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.54M $14.80M $13.20M
Total Long-Term Liabilities $3.081M $3.500M $4.100M
Total Liabilities $25.62M $18.30M $17.30M
YoY Change 40.02% -18.31% -12.67%
SHAREHOLDERS EQUITY
Retained Earnings -$458.1M -$383.2M -$362.0M
YoY Change 19.56% 41.85%
Common Stock $405.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $223.4M $22.23M $40.71M
YoY Change
Total Liabilities & Shareholders Equity $249.0M $40.52M $58.00M
YoY Change 514.51% -69.05% -39.77%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$17.98M -$21.25M -$18.99M
YoY Change -15.36% -27.38% -28.42%
Depreciation, Depletion And Amortization $752.0K $766.0K $1.334M
YoY Change -1.83% 0.26% 102.74%
Cash From Operating Activities -$18.42M -$15.57M -$13.07M
YoY Change 18.33% -19.07% -50.3%
INVESTING ACTIVITIES
Capital Expenditures -$237.0K -$80.00K -$80.00K
YoY Change 196.25% -87.69% -92.98%
Acquisitions
YoY Change
Other Investing Activities -$72.27M $0.00 $400.0K
YoY Change -100.0% -98.42%
Cash From Investing Activities -$72.51M -$80.00K $320.0K
YoY Change 90537.5% -102.02% -98.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -18.42M -15.57M -13.07M
Cash From Investing Activities -72.51M -80.00K 320.0K
Cash From Financing Activities 3.000K 0.000
Net Change In Cash -90.93M -15.65M -12.75M
YoY Change 481.03% -136.5% 493.02%
FREE CASH FLOW
Cash From Operating Activities -$18.42M -$15.57M -$13.07M
Capital Expenditures -$237.0K -$80.00K -$80.00K
Free Cash Flow -$18.19M -$15.49M -$12.99M
YoY Change 17.41% -16.68% -48.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
223363000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8872000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
134878000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
41000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
us-gaap Net Income Loss
NetIncomeLoss
-53578000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112312970
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-22000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-21246000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17983000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
223363000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57906000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
621000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
40713000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2764000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21246000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
80048000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9111000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Net Income Loss
NetIncomeLoss
-66927000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
22231000
us-gaap Profit Loss
ProfitLoss
-53578000
us-gaap Profit Loss
ProfitLoss
-66927000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-535000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
20000
us-gaap Share Based Compensation
ShareBasedCompensation
9958000
us-gaap Share Based Compensation
ShareBasedCompensation
9111000
us-gaap Depreciation
Depreciation
2204000
us-gaap Depreciation
Depreciation
3126000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
594000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
639000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4831000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2044000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-9593000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56890000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
839000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-3930000
us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-7900000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
124571000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
401000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-121262000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6660000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
134878000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
41000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
134919000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-43233000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51246000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76370000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111838000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25124000
sldb Change In Unrealized Loss
ChangeInUnrealizedLoss
-22000
sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-1233000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
345000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84462000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-458147000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-17983000
us-gaap Profit Loss
ProfitLoss
-53578000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56890000
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
229760000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, the recognition of research and development expenses and equity-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact. The Company has made estimates of the impact of COVID-19 within its financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates. </p>
CY2021Q3 us-gaap Deposit Assets
DepositAssets
2162000
CY2020Q4 us-gaap Deposit Assets
DepositAssets
327000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
90000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2072000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109676000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24797000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76043000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
90000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2072000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
327000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111838000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
155071000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25124000
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
83719000
CY2021Q3 us-gaap Exchange Fees
ExchangeFees
194000
us-gaap Exchange Fees
ExchangeFees
381000
CY2020Q3 us-gaap Exchange Fees
ExchangeFees
0
us-gaap Exchange Fees
ExchangeFees
0
CY2020Q4 sldb Common Stock Shares Issued Warrant To Purchase
CommonStockSharesIssuedWarrantToPurchase
30000
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.29
sldb Agreement Termination Period
AgreementTerminationPeriod
P60D
sldb Agreement Written Notice Period
AgreementWrittenNoticePeriod
P30D
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
120084000
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
203803000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
120106000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
120084000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
120106000
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
120084000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
120106000
sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y7M6D
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17787000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16866000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10901000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8713000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6886000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8153000
CY2021Q3 us-gaap Depreciation
Depreciation
752000
us-gaap Depreciation
Depreciation
2204000
CY2021Q3 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
4614000
CY2020Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
2674000
CY2021Q3 sldb Prepaid Tenant Improvement Allowance Receivable
PrepaidTenantImprovementAllowanceReceivable
680000
CY2021Q3 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
3072000
CY2020Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
1483000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8366000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4157000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8003000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8640000
CY2019Q3 sldb Gross Proceeds From Issuance Of Private Placement
GrossProceedsFromIssuanceOfPrivatePlacement
59977000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
458350
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3460245
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3416000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2764000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9958000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21246000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53578000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
112312970
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6244549

Files In Submission

Name View Source Status
0001564590-21-053726-index-headers.html Edgar Link pending
0001564590-21-053726-index.html Edgar Link pending
0001564590-21-053726.txt Edgar Link pending
0001564590-21-053726-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-10q_20210930.htm Edgar Link pending
sldb-10q_20210930_htm.xml Edgar Link completed
sldb-20210930.xsd Edgar Link pending
sldb-20210930_cal.xml Edgar Link unprocessable
sldb-20210930_def.xml Edgar Link unprocessable
sldb-20210930_lab.xml Edgar Link unprocessable
sldb-20210930_pre.xml Edgar Link unprocessable
sldb-ex10_162.htm Edgar Link pending
sldb-ex10_163.htm Edgar Link pending
sldb-ex311_10.htm Edgar Link pending
sldb-ex312_9.htm Edgar Link pending
sldb-ex321_6.htm Edgar Link pending
sldb-ex322_7.htm Edgar Link pending